AzTrials
AzTrials

ICUNCT07825012

External Validation of the FedHist Dynamic Early Warning Model for Mortality Risk in Critically Ill Patients: A Prospective Multicenter Study

An observational study of ICU, run by Southeast University, China.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to assess how accurately FedHist, an artificial intelligence model, predicts the risk of death in critically ill patients. Patients in intensive care units (ICUs) can become worse quickly. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
ICU
What is being tested?
Risk of mortality
How many people
23,579 participants
Where
No sites listed yet
Study dates
1 Oct 2026to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients admitted to the participating ICU

Who may be able to join

  • Admission to a participating ICU

Who cannot join

  • Age younger than 18 years.
  • Expected ICU length of stay shorter than 24 hours.
  • Refusal to provide written informed consent.

Trial locations and contacts

No sites are listed yet. Contact the study team or a site near you to ask about taking part.

About this study

The purpose of this study is to assess how accurately FedHist, an artificial intelligence model, predicts the risk of death in critically ill patients. Patients in intensive care units (ICUs) can become worse quickly. Updating risk estimates as new clinical information becomes available may help identify patients at higher risk. FedHist uses routinely collected clinical information to estimate a patient's risk of dying in the ICU within the next 24 hours. These estimates are updated every 6 hours.

This study will evaluate FedHist prospectively across several hospitals. The model will be integrated into hospital clinical information systems, and its predictions will be compared with observed patient outcomes. The study aims to determine whether FedHist provides accurate predictions across hospitals with different patient populations and clinical practices.

Read the detailed description

Critically ill patients can deteriorate rapidly, creating a need for timely and repeated assessment of mortality risk. Conventional severity assessments, including the Acute Physiology and Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure Assessment (SOFA) scores, provide clinically useful information. However, risk assessments based on data from defined assessment periods may not fully capture evolving clinical trajectories. Models that incorporate longitudinal clinical data may support more frequent assessment of short-term mortality risk.

Artificial intelligence offers opportunities to integrate clinical information collected over time for dynamic risk prediction. However, models developed using data from a single center or database may perform differently in other settings. Differences in patient characteristics, disease severity, measurement frequency, and clinical workflows can affect predictive performance. Privacy requirements, data governance policies, and institutional control over data also limit the pooling of patient records for conventional centralized model development.

FedHist was developed using a federated learning framework incorporating electronic health records from more than 250,000 critically ill patients across five countries and regions. This framework enabled collaborative model development while raw patient data remained at the contributing institutions. FedHist generates an updated estimate of the risk of ICU death within the next 24 hours at 6-hour intervals.

Previous evaluations showed a macro-averaged area under the receiver operating characteristic curve (AUROC) of 0.893 in internal validation. AUROCs were 0.881 in the NWICU external validation cohort and 0.961 in the prospective CDIC cohort. FedHist outperformed the corresponding locally trained models. When only 10% of the development data at each site were used, its performance approached or exceeded that of local models trained on the full development datasets. These findings support further prospective evaluation following integration into routine clinical information systems across multiple hospitals.

This prospective multicenter study will externally validate the previously developed FedHist model in participating ICUs. The model will be integrated into local clinical information systems to generate risk estimates using prospectively collected clinical data. Predictions will be compared with observed ICU outcomes to assess performance in predicting death within the subsequent 24 hours. The study will evaluate predictive performance across participating hospitals and assess the generalizability of FedHist under routine clinical conditions.

Conditions
ICU
Being tested
Risk of mortality

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Risk of mortalityOther

    Patients admitted to the ICU with different risk of mortality

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ICU mortality

    The proportion of patients who die from any cause during the ICU stay, with follow-up capped at 90 days after ICU admission. For patients whose ICU stay exceeds 90 days, vital status at day 90 will be used to determine the mortality outcome.

    Measured: From ICU admission to ICU discharge or 90 days after ICU admission, whichever occurs first.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Sep 2026
  2. Study start1 Oct 2026 (estimated)
  3. Primary completion1 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
23,579 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07825012
Sponsor's protocol ID
2026ZDSYLL335-P01
Status last verified
Sep 2026
First submitted
13 Sep 2026
Last updated
17 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of ICU, run by Southeast University, China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 17 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact hui chen (+86-18006138640, huichen.icu@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ICU mortality (time frame: From ICU admission to ICU discharge or 90 days after ICU admission, whichever occurs first.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in